

VICTORY : A PILOT STUDY to INVESTIGATE SAFETY and EFFICACY of WEEKLY COMBINATION of INTRAVENOUS VINBLASTINE WITH ORAL Type II RAF INHIBITOR TOVORAFENIB IN PEDIATRIC PATIENTS with RECURRENT/PROGRESSIVE RAFALTERED (non-NF1) LOW GRADE GLIOMAS

Nirav Thacker, Jordan Hansford, Daniel Morgenstern, Liana Nobre, Lucie Lafay-Cousin, Sebastien Perreault, Sylvia Cheng, Adam Fleming, Cynthia Hawkins, Anthony Liu, Santosh Valvi, Tara Mckeown, Robyn Strong, Ciara Tremblay, Aiman Siddiqi, Uri Tabori

Background

Pediatric low-grade gliomas (pLGGs) are the most common childhood brain tumors and are frequently driven by MAPK pathway alterations. Chemotherapy and targeted MAPK-directed agents have improved disease control, but durability and tolerability remain challenges. Preclinical data suggest that combining chemotherapy with targeted therapy may provide synergistic effects, offering a rational strategy to enhance efficacy. The VICTORY study is an international, multicentre trial evaluating this approach by combining weekly vinblastine with tovorafenib, a novel type II pan-RAF inhibitor.


Primary Objective

- To determine the maximum tolerated dose (MTD/RP2D) of combination of vinblastine + tovorafenib for children with recurrent/progressive LGGs.
- To assess safety and tolerability of combination of vinblastine and tovorafenib in pediatric patients with recurrent/progressive LGG.
- To determine overall response rate (ORR) of CR, PR and MR in patients with LGG treated with combination of vinblastine + tovorafenib by RANO-LGG criteria.


Salient Inclusion Criteria




Study Design



Sites



Results/Current Status



Impact/Outcomes

- **Canadian led Innovation** : VICTORY is a Canadian-developed and Canadian-led trial combining chemotherapy with targeted therapy.
- **Access to novel therapy** : Provides Canadian children access to novel pan RAF inhibitor tovorafenib
- **National Equity** : Open at 7 Canadian centres, with planned expansion, enabling coast-to-coast-coast access.
- **Accessible** : Planned satellite delivery model allows allows participation closer to home and reduce travel burden.
- **Scalable impact** : Establishes a national framework for equitable delivery of novel pediatric oncology therapies